<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818090</url>
  </required_header>
  <id_info>
    <org_study_id>KCSG-LU08-03; CRCST-L-0003</org_study_id>
    <nct_id>NCT00818090</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Cisplatin for Thymic Neoplasm</brief_title>
  <official_title>A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korean Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korean Cancer Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of the regimen in previously untreated, unresectable
      invasive thymoma or thymic carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    marginal statistical significance
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 weeks, 12 weeks, 18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>start of medication to 4 weeks since the last medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>till progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>till progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>till death, last follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Thymoma</condition>
  <condition>Thymic Carcinoma</condition>
  <arm_group>
    <arm_group_label>TP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>paclitaxel and cisplatin every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel and cisplatin</intervention_name>
    <description>paclitaxel and cisplatin every 3 weeks</description>
    <arm_group_label>TP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically or cytologically confirmed invasive thymoma or thymic carcinoma

          -  unresectable tumor: by either local invasion, distant metastasis, or recurred
             (assessed by investigator)

          -  no previous systemic treatment for invasive thymoma or thymic carcinoma

          -  at least one measurable lesion by RECIST criteria

          -  18 years old or older

          -  ECOG performance status 0, 1, 2

          -  adequate lab. findings neutrophil ≥ 1.5 x 10^9/L platelet ≥ 75 x 10^9/L hemoglobin ≥
             9.0 g/dL bilirubin ≤ 1.5 x upper normal limit AST, ALT ≤ 2.5 x upper normal limit
             Alkaline phosphatase ≤ 2.5 x upper normal limit (if liver metastasis, ≤ 5 x upper
             normal limit) serum creatinine ≤ 1.0 x upper normal limit if serum creatinine &gt; 1.0 x
             upper normal limit, creatinine clearance ≥ 60 mL/min

          -  patient who agree to written, informed consent

        Exclusion Criteria:

          -  other malignancy (exception: non-melanoma skin cancer, cervical carcinoma in situ,
             cancer without evidence more than 5 years since curative resection)

          -  active bacterial infection

          -  history of clinical trial with investigational drug within 30 days

          -  radiotherapy to thoracic or mediastinal area (other area radiotherapy is permitted)

          -  pregnant, or lactating women

          -  patient with organ transplantation

          -  peripheral neuropathy, grade 2 or greater

          -  severe, medical condition unstable cardiac disease despite of adequate management
             myocardial infarction within 6 months active ulcer disease refractory to medication
             chronic obstructive lung disease requiring admission treatment within 1 year

          -  uncontrolled seizure, cerebral nervous system disorder, psychiatric problem which
             decrease treatment compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dae Seog Heo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2009</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korean Cancer Study Group</investigator_affiliation>
    <investigator_full_name>Se-Hoon Lee</investigator_full_name>
    <investigator_title>Korean Cancer Study Group</investigator_title>
  </responsible_party>
  <keyword>thymic epithelial tumor</keyword>
  <keyword>paclitaxel</keyword>
  <keyword>cisplatin</keyword>
  <keyword>thymic carcinoma</keyword>
  <keyword>invasive thymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thymoma</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

